• Cell and gene therapies have delivered remarkable outcomes for patients with a wide variety of diseases and conditions.
• These therapies rely on adeno-associated viral (AAV) vectors and lentiviral vectors and are essential for delivery of genetic material into target cells.
• Use of adherent cell cultures for vector production are limited in terms of scalability and have historically relied on media formations that were not optimized and supplemented with fetal bovine serum.
• In contrast, suspension culture systems deliver significant benefits for upstream viral vector production processes including higher AAV and lentivirus vector titers and robust scalability.

This collection of insights, produced through a partnership between

, and Bioprocess Online, highlights strategies and guidance to ensure reliable biomanufacturing capacity and supply chains for the delivery of health technologies like vaccines, even during crisis conditions.

This post discusses the environmental challenges posed by the Biopharmaceutical industry’s heavy reliance on single-use systems and the resulting plastic waste. It highlights the industry’s quest for sustainable solutions through advanced recycling methods to achieve circularity.

In this webinar, join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and process efficiency from preclinical to commercial.

Purification efficiency evaluated endotoxin and host cell protein (HCP) clearance, plasmid yield, potential interference of the detergents with analytical in-process control assays, and overall process compatibility, and this comprehensive screening approach provides valuable insights to intensified plasmids production.

BioLabs builds innovation communities around Biotech entrepreneurs providing them with infrastructure, support, and networking to successfully succeed. Hear how BioLabs has launched 15 sites in the US, Europe and Asia with internationally known strategic partners.

Single-source manufacture of biopharmaceuticals is becoming more and more rare. Increasingly, biomanufacturers or “sponsor” companies partner with contract…

The covid-19 pandemic forced rapid vaccine development and market approval, shortening a process that normally takes years to just a few months. This experience raises a tantalising question: can such speed be sustained for other treatments?

Insights on the changes in the biotech VC landscape and tips from an investor perspective for companies fundraising now.

Check out this article where

‘s Eva Schaefer, Director of Supply Robustness, and Tom Elich, MSAT Manager, discuss how industry collaboration has never been more important.